We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
FRSOB | Forrestania Resources Ltd | 0.01 | 0.008 | 400.00% | 9,585,871 | 43 |
FRSOA | Forrestania Resources Ltd | 0.006 | 0.004 | 200.00% | 4,322,578 | 36 |
CAQ | CAQ Holdings Limited | 0.071 | 0.044 | 162.96% | 568,946 | 17 |
AS2O | Askari Metals Ltd | 0.005 | 0.003 | 150.00% | 15,000 | 1 |
FRS | Forrestania Resources Ltd | 0.045 | 0.026 | 136.84% | 78,642,571 | 1,764 |
TMKOB | TMK Energy Ltd | 0.002 | 0.001 | 100.00% | 2,794,436 | 4 |
AUNOC | Aurumin Limited | 0.002 | 0.001 | 100.00% | 11,671,509 | 18 |
AUZOB | Australian Mines Ltd | 0.002 | 0.001 | 100.00% | 2,026,413 | 5 |
BRXOA | Belararox Ltd | 0.065 | 0.024 | 58.54% | 10,000 | 1 |
MTMO | MTM Critical Metals Ltd | 0.003 | 0.001 | 50.00% | 500,000 | 1 |
VPR | Volt Power Group Limited | 0.0015 | 0.0005 | 50.00% | 601,419 | 13 |
—Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— —Treatment with Brensocatib Also Achieves Statistical Significance on Multiple Secondary Endpoints for Both Dosage Strengths Versus Placebo— —Brensocatib Well-Tolerated at Both Dosage Strengths— —Results from ASPEN Validate DPP1 Inhibition as New Mechanism of Action with Potential to Address Range of Neutrophil-Mediated Diseases— —Insmed Plans to Advance Quickly Toward U.S. Regulatory Filing, with Anticipated U.S. Launch in Mid-2025, Pending Approval— —Insmed to Host Investor Call at 8:00 am ET on Tuesday, May 28, 2024— BRIDGEWATER, ...
STOCKHOLM, May 28, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced the presentations of an additional efficacy analysis of Nefecon (TARPEYO® (budesonide) delayed release capsules)) as well as a real-world analysis of the use of systemic glucocorticoids (SGC) in IgA nephropathy (IgAN). These were presented at ERA 2024 virtually and in Stockholm on May 23 - 26, 2024.
TORONTO, May 28, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries in Canada and market partners in China, today announced the Company has successfully transformed into a high-innovation and high growth company.
SANTA CLARA, Calif., May 28, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, announced today that its board of directors has adopted bitcoin as its primary treasury reserve asset. In addition, Semler Scientific announced that it has purchased 581 bitcoins for an aggregate amount of $40 million, inclusive of fees and expenses.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 67,878.53 | -1,514.66 | -2.18% | 1.34T | 4,261,257,483 |
ETH | Ethereum | 3,831.58 | -60.03 | -1.54% | 461.87B | 3,065,995,826 |
USDT | Tether USD | 0.99907 | -0.00012 | -0.01% | 97.75B | 155,752,023 |
BNB | Binance Coin | 598.91 | -4.50 | -0.75% | 94.65B | 235,086,527 |
SOL | Solana | 167.15 | -2.90 | -1.71% | 74.23B | 997,291,337 |
STETH | stETH | 3,805.81 | -85.02 | -2.19% | 37.69B | 9,900,980 |
XRP | Ripple | 0.5273 | -0.0064 | -1.20% | 28.8B | 271,700,635 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 878,595,975 |
DOGE | Dogecoin | 0.16267 | -0.00639 | -3.78% | 23.37B | 463,518,253 |
TONCOIN | Wrapped TON Coin | 6.37 | -0.162029 | -2.48% | 22.16B | 50,678,450 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions